TRCT
UTMD icon

Tower Research Capital (TRC)’s Utah Medical Products UTMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2K Buy
536
+329
+159% +$20.7K ﹤0.01% 3097
2025
Q4 		$11.6K Sell
207
-27
-12% -$1.56K ﹤0.01% 3575
2025
Q3 		$14.7K Sell
234
-452
-66% -$26.7K ﹤0.01% 3577
2025
Q2 		$39K Buy
686
+444
+183% +$24.1K ﹤0.01% 3190
2025
Q1 		$13.6K Sell
242
-276
-53% -$16.5K ﹤0.01% 3350
2024
Q4 		$31.8K Buy
518
+328
+173% +$21.2K ﹤0.01% 2864
2024
Q3 		$12.7K Sell
190
-338
-64% -$22.9K ﹤0.01% 3567
2024
Q2 		$35.3K Buy
528
+507
+2,414% +$34.5K ﹤0.01% 3364
2024
Q1 		$1.49K Sell
21
-130
-86% -$9.75K ﹤0.01% 5257
2023
Q4 		$12.7K Sell
151
-1,298
-90% -$108K ﹤0.01% 4024
2023
Q3 		$125K Buy
1,449
+1,252
+636% +$116K ﹤0.01% 1810
2023
Q2 		$18.4K Sell
197
-31
-14% -$2.92K ﹤0.01% 3463
2023
Q1 		$22K Buy
228
+141
+162% +$13K ﹤0.01% 3355
2022
Q4 		$9K Sell
87
-186
-68% -$17K ﹤0.01% 4279
2022
Q3 		$23K Buy
273
+66
+32% +$5.83K ﹤0.01% 3829
2022
Q2 		$18K Sell
207
-47
-19% -$4.01K ﹤0.01% 3917
2022
Q1 		$23K Sell
254
-149
-37% -$13.7K ﹤0.01% 3407
2021
Q4 		$41K Buy
403
+222
+123% +$22.7K ﹤0.01% 2928
2021
Q3 		$17K Sell
181
-217
-55% -$19.2K ﹤0.01% 3885
2021
Q2 		$34K Sell
398
-49
-11% -$4.24K ﹤0.01% 3365
2021
Q1 		$39K Sell
447
-1,054
-70% -$92.7K ﹤0.01% 3339
2020
Q4 		$127K Sell
1,501
-2,390
-61% -$204K ﹤0.01% 2122
2020
Q3 		$311K Buy
3,891
+2,310
+146% +$192K ﹤0.01% 2151
2020
Q2 		$140K Buy
+1,581
New +$142K 0.01% 2148
2019
Q4 		– Sell
-100
Closed -$10K – 4409
2019
Q3 		$10K Buy
+100
New +$9.29K ﹤0.01% 2952
2019
Q2 		– Sell
-22
Closed -$2K – 4332
2019
Q1 		$2K Sell
22
-304
-93% -$26.7K ﹤0.01% 3463
2018
Q4 		$27K Buy
+326
New +$28.7K ﹤0.01% 1717
2018
Q3 		– Sell
-2,137
Closed -$235K – 4272
2018
Q2 		$235K Buy
+2,137
New +$223K 0.01% 1008
2018
Q1 		– Sell
-696
Closed -$57K – 3860
2017
Q4 		$57K Buy
696
+496
+248% +$38.7K 0.01% 1242
2017
Q3 		$15K Buy
200
+127
+174% +$9.13K ﹤0.01% 2896
2017
Q2 		$5K Sell
73
-55
-43% -$3.62K ﹤0.01% 2021
2017
Q1 		$8K Buy
+128
New +$8.06K ﹤0.01% 1939
2016
Q4 		– Sell
-121
Closed -$7K – 4428
2016
Q3 		$7K Sell
121
-379
-76% -$24.1K ﹤0.01% 2354
2016
Q2 		$31K Buy
+500
New +$32.2K ﹤0.01% 1913
2016
Q1 		– Sell
-33
Closed -$2K – 4976
2015
Q4 		$2K Sell
33
-237
-88% -$13.4K ﹤0.01% 3819
2015
Q3 		$15K Buy
270
+19
+8% +$1.04K ﹤0.01% 1990
2015
Q2 		$15K Buy
251
+23
+10% +$1.29K ﹤0.01% 2362
2015
Q1 		$14K Buy
228
+163
+251% +$9.58K ﹤0.01% 2537
2014
Q4 		$4K Sell
65
-1,866
-97% -$103K ﹤0.01% 2931
2014
Q3 		$94K Buy
1,931
+1,890
+4,610% +$96K 0.01% 1032
2014
Q2 		$2K Sell
41
-619
-94% -$31.8K ﹤0.01% 3468
2014
Q1 		$38K Sell
660
-222
-25% -$12.1K ﹤0.01% 1303
2013
Q4 		$50K Buy
882
+579
+191% +$31.8K 0.01% 1400
2013
Q3 		$18K Buy
303
+116
+62% +$6.33K ﹤0.01% 2780
2013
Q2 		$10K Buy
+187
New +$8.8K ﹤0.01% 2385

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s UTMD Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Utah Medical Products (UTMD) stake by 159% in Q1 2026, buying an estimated $20.7K and bringing the position to 536 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3097.

Tower Research Capital (TRC) first reported a position in UTMD in Q2 2013 and has held it in 45 quarters since. The position peaked at $311K in Q3 2020. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Tower Research Capital (TRC) held 536 shares of Utah Medical Products worth $33.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 329 Utah Medical Products shares in Q1 2026, an estimated $20.7K.
  • Utah Medical Products made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3097 holding.
  • Tower Research Capital (TRC) first reported a position in Utah Medical Products in Q2 2013 and has held it in 45 quarters since.
  • Tower Research Capital (TRC)'s Utah Medical Products position peaked at $311K in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.